Loading
The receptor that tells the bone marrow to make neutrophils. Filgrastim and pegfilgrastim stimulate it to shorten the dangerous low-neutrophil period after chemotherapy, cutting the risk of febrile neutropenia.
The granulocyte colony-stimulating factor receptor on myeloid progenitors drives neutrophil production and release through JAK2 and STAT3 signalling. Recombinant G-CSF (filgrastim) and its long-acting pegylated form (pegfilgrastim) are given after myelosuppressive chemotherapy to shorten neutropenia and are recommended when the regimen carries a high risk of febrile neutropenia. They also mobilise stem cells before autologous transplantation. Activating CSF3R mutations define chronic neutrophilic leukaemia, which responds to the JAK inhibitor ruxolitinib.
In plain words · The receptor that tells the bone marrow to make neutrophils. Filgrastim and pegfilgrastim stimulate it to shorten the dangerous low-neutrophil period after chemotherapy, cutting the risk of febrile neutropenia.
The receptor that tells the bone marrow to make neutrophils. Filgrastim and pegfilgrastim stimulate it to shorten the dangerous low-neutrophil period after chemotherapy, cutting the risk of febrile neutropenia.
Cytokine receptor on neutrophil progenitors signalling through JAK2 and STAT3; agonised by recombinant G-CSF.
2 products aim at G-CSF receptor (CSF3R): antibodies and other agents. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Lineage antigen shared with normal granulocytes: HPA blood lineage lineage enriched at or above 25 nTPM, and 1 antibody (Eflapegrastim) aim at it, so normal cells of the lineage are hit too. HPA CSF3R: RNA tissue enhanced (bone marrow 184 nTPM, lung 134 nTPM, lymphoid tissue 375 nTPM); blood lineage lineage enriched (granulocytes 1,924 nTPM); high antibody staining in 1 normal tissue. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Myeloid neoplasms); approvals of single-target medicines aimed at it also list Breast cancer (all types), not counted; Open Targets associates it with 2 specific cancer types at or above 0.5 (myelodysplastic syndrome, acute myeloid leukemia); the corpus evidence decides and the Open Targets list is quoted for comparison. (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas CSF3R tissue; Human Protein Atlas CSF3R pathology; Open Targets ENSG00000119535 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Larsen et al, J. Exp. Med, 1990, "Expression cloning of a human granulocyte colony-stimulating factor receptor: a structural mosaic of hematopoietin receptor, immunoglobulin, and fibronectin domains". Source.
Cytokine receptor on neutrophil progenitors signalling through JAK2 and STAT3; agonised by recombinant G-CSF.
RNA: tissue enhanced (bone marrow 184 nTPM, lung 134 nTPM, lymphoid tissue 375 nTPM), detected in many normal tissues. Blood: lineage enriched (granulocytes 1,924 nTPM).
Medium: Cerebral cortex, Heart muscle, Skin, Testis.
No cancer stained high; medium in urothelial cancer.
HPA CSF3R tissue · HPA CSF3R pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Myeloproliferative neoplasms | 59% | Activating CSF3R mutation in chronic neutrophilic leukaemia or atypical BCR-ABL1-negative CML, 16 of 27 patients | Two mutation regions with different kinase dependencies (SRC family or JAK); ruxolitinib response reported in a JAK-type case | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Eflapegrastim is a once-per-cycle white cell growth factor approved in the United States in 2022 to prevent infections when chemotherapy for solid tumours knocks down neutrophils, an alternative to pegfilgrastim.
Lenograstim is Europe's and Japan's glycosylated form of G-CSF, given after chemotherapy to shorten the period of dangerously low neutrophils and to mobilise stem cells for transplant; it does the same job as filgrastim.
Query for this target: (TITLE:"G-CSF receptor" OR ABSTRACT:"G-CSF receptor" OR TITLE:"CSF3R" OR ABSTRACT:"CSF3R") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about G-CSF receptor (CSF3R), not a curated reading list.
Shares Pegfilgrastim, Filgrastim (G-CSF).
Shares Lenograstim, Pegfilgrastim.
Shares Lenograstim, Pegfilgrastim.
Shares Lenograstim, Pegfilgrastim.
Shares Febrile neutropenia, Neutropenia.
Shares Pegfilgrastim, Filgrastim (G-CSF).
Shares Febrile neutropenia, Neutropenia.
Shares Pegfilgrastim, Filgrastim (G-CSF), Febrile neutropenia, Neutropenia.